Azacitidine filed for myelodysplastic syndrome in Japan
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku has filed an approval application in Japan for azacitidine (NS-17) for the treatment of myelodysplastic syndrome (MDS). The product, licensed from Pharmion (now part of Celgene), is already marketed in around 20 countries, including in the US as Vidaza.